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Executive function deficits, such as working memory, decision-making, and attention 
problems, are a common feature of several psychiatric disorders for which no satisfactory 
treatment exists. Here, we transdiagnostically investigate the effects of pharmacological 
interventions (other than methylphenidate) on the fronto-cingulo-parietal cognitive control 
network, in order to identify functional brain markers for future procognitive pharmaco-
logical interventions. Twenty-nine manuscripts investigated the effect of pharmacological 
treatment on executive function-related brain correlates in psychotic disorders (n = 11), 
depression (n =  4), bipolar disorder (n =  4), ADHD (n =  4), OCD (n =  2), smoking 
dependence (n = 2), alcohol dependence (n = 1), and pathological gambling (n = 1). In 
terms of impact on the fronto-cingulo-parietal network, the preliminary evidence for cat-
echol-O-methyl-transferase inhibitors, nicotinic receptor agonists, and atomoxetine was 
relatively consistent, the data for atypical antipsychotics and anticonvulsants moderate, 
and interpretation of the data for antidepressants was hampered by the employed study 
designs. Increased activity in task-relevant areas and decreased activity in task-irrelevant 
areas were the most common transdiagnostic effects of pharmacological treatment. 
These markers showed good positive and moderate negative predictive value. It is 
concluded that fronto-cingulo-parietal activity changes can serve as a marker for future 
procognitive interventions. Future recommendations include the use of randomized 
double-blind designs and selective cholinergic and glutamatergic compounds.
Keywords: psychopharmacology, fMRi, psychiatric disorders, attention, cognition, prefrontal cortex, executive 
functioning, treatment
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iNTRODUCTiON
How are pharmacological interventions for psychiatric disorders 
related to changes in functional brain correlates of executive 
functions? Impairments in executive functions, such as working 
memory, decision-making, planning, and attention, are a com-
mon feature of several psychiatric disorders. Extensive evidence 
in depression (1, 2), schizophrenia (SCZ) and psychosis (3, 4), 
bipolar disorder (5, 6), obsessive–compulsive disorder (OCD) 
(7, 8), substance dependence (9, 10), anxiety (11), autism 
spectrum disorders (12, 13), and attention-deficit/hyperactivity 
disorder (ADHD) (14, 15) suggests consistent impairments on 
a broad range of neuropsychological tests. For many of these 
disorders, there is compelling evidence that executive function 
deficits may be present before illness onset (16–18) and often 
persist beyond the acute phase of the disease (9, 19–21). With 
the exception of ADHD, there currently exists no successful 
pharmacological treatment for executive function deficits in 
psychiatric disorders.
The fact that assessments of executive functions in psychiatric 
disorders predict relapse/remission (9, 22, 23), functional out-
come (24, 25), and in some cases, treatment response (26, 27) 
suggests that it is a core transdiagnostic symptom domain that 
requires adequate treatment. Recent reviews have suggested that 
increasing patient functioning and outcome may be achieved by 
boosting executive functions (28, 29), further increasing attrac-
tiveness of this symptom domain as a treatment target.
Then, do the available pharmacological interventions for the 
treatment of psychiatric disorders modulate executive function 
deficits? Based on the available literature, especially the dopa-
mine- and noradrenaline-increasing effects of methylphenidate 
(MPH) have been consistently associated with normalizing 
effects in ADHD (30, 31) and procognitive effects in healthy 
volunteers (32). And, many other pharmacological agents with 
glutamatergic [e.g., memantine (33)], cholinergic [e.g., rivastig-
mine (33)], dopaminergic [e.g., modafinil (34) and atomoxetine 
(35)], and noradrenergic [e.g., atomoxetine (35)] properties have 
also been shown to modulate executive functions. Moreover, 
while not the primary aim of these agents, there is evidence for 
a modest improvement in some executive function domains for 
atypical antipsychotics (36), likely related to their dopamine- and 
serotonin-modulating properties.
It may be the case that pharmacological agents for psychi-
atric disorders, which may or may not have the primary aim to 
modulate executive functions, at least partly impact common 
substrates. Although executive functions are underlain by widely 
distributed networks, one brain network consistently associated 
with executive functions is the fronto-cingulo-parietal cognitive 
control network (37). Essential hubs in the fronto-cingulo-
parietal network have consistently been associated with execu-
tive function domains such as the anterior cingulate cortex with 
cognitive control (38), dorsolateral prefrontal cortex (DLPFC) 
with working memory (37, 39), inferior frontal gyrus (IFG) and 
(pre-)supplementary motor area (SMA) with response inhibi-
tion (40–42), and the parietal lobules with visual attention and 
attention control (43, 44). As such, the fronto-cingulo-parietal 
network is ideally suited as a reference network, which can be 
used to evaluate the effect of pharmacological agents on executive 
function-related brain networks.
While especially the effect of MPH on cognitive control 
networks has been critically evaluated in relation to its phar-
macological mechanism (30, 31), the aim of the current review 
was to systematically review the evidence for other available 
pharmacological interventions in a transdiagnostic fashion. This 
includes not only pharmacological agents with demonstrated 
procognitive effects but also agents that are not primarily used 
to ameliorate executive function deficits, such as antidepressants 
or antipsychotics. Relating plausible mechanisms of action to the 
effect of pharmacological interventions on functional brain cor-
relates of executive functions could assist in further (I) validating 
the therapeutical effects of these agents and (II) elucidating brain 
mechanisms that could be targeted by future procognitive agents.
The use of functional magnetic resonance imaging (fMRI) to 
investigate brain correlates of executive functions is well estab-
lished (45). More recently, this method has increasingly been 
used to evaluate the effects of pharmacological agents on brain 
function (46, 47). The strength of pharmacological fMRI is its 
ability to quantify activity changes in functional brain networks 
related to direct or downstream consequences of the pharmaco-
logical intervention. This enables the investigation of common 
and distinct drug effects on functional brain networks.
In this transdiagnostic systematic review, we aim to provide an 
overview of the effects of pharmacological interventions (other 
than MPH) on the fronto-cingulo-parietal cognitive control 
network in psychiatric disorders and to relate these to plausible 
neuropharmacological mechanisms. Using recent meta-analyses, 
we start off with a brief definition of the fronto-cingulo-parietal 
network. Next, we specifically evaluate original studies employing 
strictly executive functioning fMRI paradigms before treatment 
and after stable therapeutically efficacious dosing (monotherapy 
or adjunctive) had been implemented. We conclude with com-
mon transdiagnostic effects of pharmacological agents on the 
fronto-cingulo-parietal network, which could serve as markers 
for future procognitive interventions.
MeTHODS
PubMed was searched for studies published before October 23, 
2015 using the initial Boolean phrase: (“fMRI” OR “functional 
magnetic resonance imaging”) AND (“cognition” OR “work-
ing memory” OR “attention” OR “decision-making” or “verbal 
learning” or “vigilance” or “processing speed” or “reasoning” or 
“problem solving” or “social cognition” or “verbal memory” or 
“visual learning” or “visual memory”) AND (“treatment”) AND 
(“pharmacology”). We followed up this initial search with a num-
ber of targeted searches in psychiatric disorders. To these aims, 
we replaced (“treatment”) AND (“pharmacology”) with (“phar-
macology” OR “treatment”) AND (i) (“depression” OR “MDD”), 
(ii) (“schizophrenia” OR “psychosis”), (iii) (“bipolar” OR “mania” 
OR “cyclothymia” OR “rapid cycling”), (iv) (“substance depend-
ence” OR “addiction” OR “substance abuse” OR “alcoholism”), (v) 
(“Tourette syndrome” OR “Tourette” OR “tic”), (vi) (“borderline” 
OR “personality disorder”), (vii) (“autism” OR “pervasive devel-
opmental disorder” OR “Asperger”), (viii) (“obsessive compulsive 
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disorder” OR “OCD” OR “impulse control”), (ix) (“PTSD” or 
“post traumatic stress disorder”), and (x) (“anxiety” OR “fear” 
OR “phobia”). Titles and abstracts of all results were screened. 
Cross-referencing was performed on all included manuscripts 
and relevant reviews. Given the high number of recent meta-
analyses and systematic reviews on the subject (30, 31, 48), we did 
not systematically review results of MPH treatment in psychiatric 
disorders. Treatments other than MPH in ADHD were included 
in the review if they met criteria.
Manuscripts were only considered if
 (i) they were published in a peer-reviewed journal.
 (ii) they were written in the English language.
 (iii) they used the same fMRI paradigm at baseline and follow-up.
 (iv) they reported group-level statistics; case studies were not 
included.
 (v) pharmacological agents were specified, and results of the 
medicated group were reported (e.g., manuscripts combin-
ing samples of non-pharmacologically and pharmacologi-
cally treated patients were excluded).
 (vi) the entire sample of patients was drug-free (in the case of 
monotherapy) or on stable monotherapy (in the case of 
adjunctive therapy) at baseline (washout allowed if neces-
sary) and were stably and actively on (adjunctive) medica-
tion (no washout) during follow-up session(s). Concretely, 
“stably on medication” refers to repeated administration 
(>1; single dosing studies excluded) of the same efficacious 
drug dose.
 (vii) they used fMRI paradigms that only measured aspects of 
executive functions. Tasks with stressful, painful, emotional, 
and/or rewarded components were excluded.
 (viii) participants had a diagnosis of a psychiatric disorder 
according to DSM-IV criteria. Neurological disorders, such 
as stroke, dementia, and Parkinson’s disease, were excluded.
Definition of and Rationale for the 
Cognitive Control Network as a Reference 
Network
The functional brain networks underlying higher cognitive and 
attention functions are widespread and complex with among 
others demonstrated cerebellar (49), occipital cortex (50, 51), 
striatal (52), and frontal cortical (39) involvement. In order to 
provide a clear delineation of the topic and facilitate the use of 
a reference network, we decided to review the effect of pharma-
cological agents on the fronto-cingulo-parietal cognitive control 
network. The cognitive control network has been hypothesized 
to play an essential role in orchestrating higher order behavior 
such as decision-making, action selection, and working memory 
(53). A comprehensive meta-analysis by Niendam et al. (37) dem-
onstrated recurrent activity of a fronto-cingulo-parital cognitive 
control network during paradigms that assess working memory, 
response inhibition, behavioral flexibility, and other higher order 
skills (37). These results are in line with previous meta-analyses on 
functional brain networks underlying working memory, response 
inhibition, and selective attention, specifically and consistently 
revealing ACC, DLPFC, and superior and inferior parietal lobule 
(IPL) activity (41, 54–56). Therefore, the reported results in 
this manuscript (Table 1) include observed changes in parietal 
cortex (superior and IPL), insula, ACC, and frontal cortical areas, 
including DLPFC, ventrolateral PFC (VLPFC), and orbitofrontal 
cortex (OFC). In the discussion, these results will be linked to 
other notable findings of the available studies.
ReSULTS
The review was carried out according to PRISM (57) guidelines. 
The literature search in PubMed yielded 586 unique hits, of which 
557 were excluded because they did not (i) utilize a pharmaco-
logical intervention or used MPH (38.2%), (ii) recruit patient 
populations (28.5%), (iii) employ a longitudinal fMRI design 
(17.8%), (iv) utilize a repeated dosing scheme (8.3%), (v) employ 
strictly cognitive tasks (4.4%), or (vi) were not written in the 
English language (2.8%). Thus, 29 manuscripts were included 
in this review, of which 26 used unique samples. In total, 431 
individuals were scanned while medication free or on stable 
monotherapy at baseline and on monotherapy or adjunctive 
treatment at follow-up, in addition to placebo-treated patients 
and healthy volunteers.
Study designs, tasks, sample size, medication distribution, and 
main findings of the included studies are reported in Table 1. If 
available, results regarding (i) changes over time in patients vs. 
controls and (ii) patients vs. controls at follow-up were reported. 
Else, results regarding (i) change over time in patients and (ii) 
patients at follow-up vs. controls at follow-up, or (iii) patients at 
follow-up vs. controls at baseline were reported.
Acetylcholinesterase inhibitors
Three studies (two unique samples) investigated the effect of 
adjunctive actylcholinesterase inhibitors on executive function-
related brain correlates before and after treatment. All studies 
were conducted in SCZ, and a total of 17 patients who were on 
stable antipsychotic medication were scanned before and after 
adjunctive treatment with actylcholinesterase inhibitors. Six 
patients were administered donepezil; the remaining 11 patients 
received rivastigmine.
Psychotic Disorders
None of the reported studies observed significant changes in 
task performance between placebo and medication sessions or 
between groups.
In a crossover design, Nahas et al. (58) investigated the effect of 
12-week adjunctive donepezil treatment on verbal fluency-related 
brain activity. On donepezil relative to placebo, participants 
displayed increased left IFG and insula activity.
Aasen et al. (59) investigated brain activity during a number 
detection task in a 12-week rivastigmine trial. At follow-up and 
relative to placebo-treated patients, rivastigmine-treated patients 
did not show changes in fronto-cingulo-parietal activity. On 
the n-back task, which assesses selective attention and working 
memory, Kumari et  al. (60) found a smaller increase in right 
superior frontal gyrus (SFG) activity from baseline to follow-up 
in the same sample of rivastigmine-treated patients, relative to 
placebo-treated patients.
TABLe 1 | Overview of the effect of pharmacological agents on the fronto-cingulo-parietal cognitive control network.
Reference Diagnosis N 
(treated)
N 
(PLC 
arm)
N 
(CTRL 
arm)
Study design Treatment Duration Task Main behavioral 
results
Main fMRi results Timepoint 
and/or group 
comparisons
Task contrast
Acetylcholinesterase inhibitors
Nahas et al. 
(58)
SCZ (atypical 
antipsychotics)
6 – – Randomized 
double-blind 
PLC-controlled 
crossover design
Donepezil 
adjunctive 
treatment
12 weeks Covert verbal 
fluency task
No changes in task 
performance over time
On donepezil relative to 
PLC, ↑ left IFG and left 
insula activity
Patients (donepezil 
vs. PLC)
Word generation 
vs. rest
Aasen et al. 
(59)A
SCZ 
(antipsychotics)
11 9 – Randomized 
double-blind PLC-
controlled trial
Rivastigmine 
adjunctive 
treatment
12 weeks Number 
detection task
No (between-group) 
differences in task 
performance (over time)
– – –
Kumari et al. 
(60)A
SCZ (atypical 
antipsychotics)
11 10 – Randomized 
double-blind PLC-
controlled trial
Rivastigmine 
adjunctive 
treatment
12 weeks n-back No (between-group) 
differences in task 
performance (over time)
Over time and relative to 
PLC patients at T1, no ↑ 
in right SFG activity
Rivastigmine (T0, T1) 
vs. PLC (T0, T1)
1-back vs. rest
Anticonvulsants
Pavuluri 
et al. (61)
BD (pediatric; 
mania or mixed)
13 – 13; T0, 
T1
Open-label trial Typical 
antipsychotics 
(weeks 1–4); 
lamotrigine 
(weeks 1–14)
14 weeks Go/no go Overall relative to 
CTRL, ↓ accuracy on 
No Go trials
Over time and relative 
to CTRL, greater ↑ in 
left PFC and right MFG 
activity
Lamotrigine (T0–T1) 
vs. CTRL (T0–T1)
Go vs. No Go
Over time and similar to 
CTRL, ↑ accuracy on 
Go trials
At T1 relative to CTRL, ↑ 
left M1* activity
Lamotrigine (T1) vs. 
CTRL (T0)
Go vs. No Go
Pavuluri 
et al. (62)C
BD (pediatric; 
mania or mixed)
11 – 14; T0, 
T1
Randomized 
double-blind trial
Divalproex 6 weeks Go/no go At T0 relative to 
CTRL, ↓ discrimination 
sensitivity; comparable 
to CTRL at T1E
Over time relative to 
CTRL, greater ↑ in left 
subgenual ACC and left 
insula FC in affective 
network
Divalproex (T0–T1) 
vs. CTRL (T0–T1)
During response 
inhibition
Schneider 
et al. (63)
BD (pediatric; 
mania or mixed)
10 – 9; T0 Open-label trial Carbamazepine 8 weeks CPT – identical 
pairs
At T0 and T1 relative to 
CTRL at T0, ↓ accuracy
Over time, ↑ anterior 
PFC activity; n.s. at T1 
relative to CTRL at T0
Carbamazepine (T0–
T1); carbamazepine 
(T1) vs. CTRL (T0)
1-back vs. “1” 
detection
Antidepressants: selective serotonin reuptake inhibitors and serotonin–noradrenaline reuptake inhibitors
Walsh et al. 
(64)
Major 
depression
20 – 20; 
T0–T2
Open-label trial Fluoxetine 8 weeks n-back Over time relative 
to CTRL, ↑ 3-back 
accuracy; At T0–T2 
relative to CTRL, ↑ 
reaction times
– – –
Aizenstein 
et al. (65)
Late-life 
depression
13 – 13; T0 Open-label trial Paroxetine 12 weeks Spatial 
incompatibility 
task
At T1 relative to CTRL 
at T0, ↓ accuracy 
Over time, ↑ right 
DLPFC activity; at T1 
relative to CTRL at T0, ↓ 
left DLPFC activity
Paroxetine (T0 vs. 
T1); paroxetine (T1) 
vs. CTRL (T0)
Contralateral 
vs. baseline, 
ipsilateral vs. 
baseline
Wagner 
et al. (66)D
Major 
depression
12 – 20; T0 Open-label trial Citalopram 6 weeks Stroop color-
word task
Over time, greater ↓ 
in reaction time for 
incongruent trials, 
relative to congruent 
trialsF
Over time, ↓ right 
VLPFC, SMA, IPL, and 
SPL activity
Citalopram (T0 vs. 
T1); citalopram (T0, 
T1) vs. reboxetine 
(T0, T1)
During 
incongruent 
condition
(Continued)
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Reference Diagnosis N 
(treated)
N 
(PLC 
arm)
N 
(CTRL 
arm)
Study design Treatment Duration Task Main behavioral 
results
Main fMRi results Timepoint 
and/or group 
comparisons
Task contrast
At T1 relative to CTRL 
at T0, n.s. group 
differencesF
Patients (T1) vs. 
CTRL (T0)
During 
incongruent 
condition
Gyurak et al. 
(67)
Major 
depression
79 – 34; T0, 
T1
Randomized 
open-label trial
Escitalopram 
(n = 26), 
Sertraline 
(n = 27), 
Venlafaxine ER 
(n = 26)
8 weeks Go/No Go – Over time, remitters and 
CTRL show ↓ DLPFC 
activity; over time, no 
change in hypo-DLPFC 
activity of non-remitters
CTRL (T0 vs. T1); 
remitted (T0, T1) vs. 
non-remitted (T0, T1)
Go vs. No Go
At T0 and T1, n.s. group 
differences in IPL activity 
between SSRI remitters 
and CTRL
Remitted (T0/T1) vs. 
CTRL (T0/T1)
Go vs. No Go
At T0, ↓ IPL activity 
in SNRI remitters 
than CTRL and SSRI 
remitters
Treatment (SSSRI, 
SNRI) vs. status 
(remitted, non-
remitted, CTRL) vs. 
time (T0, T1)
Go vs. No Go
At T1, ↓ IPL activity in 
SNRI remitters than in 
CTRL
van der Wee 
et al. (68)
OCD 14 – – Randomized 
double-blind trial
Paroxetine 
(n = 9), 
venlafaxine 
(n = 5)
12 weeks n-back Over time, responders, 
but not non-
responders, ↑ accuracy
Over time and relative 
to non-responders, ↓ 
mean fronto-cingulo-
parietalG activity
Remitted (T0, T1) vs. 
non-remitted (T0, T1)
2-back vs. 
0-back, 1-back 
vs. 0-back
Han et al. 
(69)
OCD 10 – 20; T0 Open-label trial Escitalopram 
(n = 9), 
fluoxetine (n = 1)
16 weeks Task-switching 
paradigm
At T0 and T1 relative to 
CTRL, ↓ accuracy. Over 
time, ↓ task-switching 
costs (RT) 
Over time, ↑ right ACC, 
right insula, right PCG, 
and right PC activity
Patients (T0 vs. T1) Task switching 
vs. task-repeat
At T1 relative to CTRL at 
T0, ↓ DLPFC†, DMPFC†, 
right MFC† and PC† 
activity, and ↑ left insula* 
activity
Patients (T1) vs. 
CTRL (T0)
Task switching 
vs. task-repeat
Atypical antipsychotics
Pavuluri 
et al. (62)C
BD (pediatric; 
mania or mixed)
11 – 14; T0 
and T1
Randomized 
double-blind trial
Risperidone 6 weeks Go/no go At T0 relative to 
CTRL, ↓ discrimination 
sensitivity; comparable 
to CTRL at T1E
Over time relative to 
CTRL, greater ↑ in 
insular FC in affective 
network
Risperidone (T0–T1) 
vs. CTRL (T0–T1)
During response 
inhibition
Schneider 
et al. (63)
BD (pediatric; 
mania or mixed)
10 7 10; T0 Randomized 
double-blind PLC-
controlled trial
Ziprasidone 4 weeks CPT – identical 
pairs
No between-group 
differences in task 
performance (over time)
Over time relative to 
PLC patients, greater 
↑ in right VLPFC/OFC 
activity
Ziprasidone (T0–T2) 
vs. PLC (T0–T2)
1-back vs. “1” 
detection
TABLe 1 | Continued
(Continued)
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Reference Diagnosis N 
(treated)
N 
(PLC 
arm)
N 
(CTRL 
arm)
Study design Treatment Duration Task Main behavioral 
results
Main fMRi results Timepoint 
and/or group 
comparisons
Task contrast
At T1 and T2 compared 
to CTRL at T0, n.s. 
group differences in 
VLPFC/OFC activity
Patients (T0/T1/T2) 
vs. CTRL (T0)
1-back vs. “1” 
detection
Snitz et al. 
(70)
FEP 11 – 16; T0 
and T1
Open-label trial Risperidone 
(n = 7); 
olanzapine 
(n = 3); 
quetiapine 
(n = 1)
4 weeks Spatial 
incompatibility 
task
At T0 and T1 relative to 
CTRL, ↑ reaction times
Over time, ↑ ACC, but 
not DLPFC, activity
Patients (T0 vs. T1) Contralateral 
vs. baseline, 
ipsilateral vs. 
baseline
At T1 relative to CTRL, 
n.s. group differences in 
DLPFC and ACC activity
Patients (T1) vs. 
CTRL (T1)
Contralateral 
vs. baseline, 
ipsilateral vs. 
baseline
Meisenzahl 
et al. (71)
SCZ 12 – 12; T0 Open-label trial Quetiapine 12 weeks n-back 
(degraded and 
non-degraded)
No (between-group) 
differences in task 
performance (over time)
Over time, ↑ left 
VLPFC (non-degraded) 
and right precuneus 
(degraded) activity
Quetiapine (T0 vs. 
T1)
2-back vs. 
0-back
Keedy et al. 
(72)
FEP 9 – 9; T0 
and T1
Open-label trial Risperidone 
(n = 6), 
ziprasidone 
(n = 1), 
haloperidol 
(n = 2)
4–6 weeks Visual attention 
task
– Over time, ↑ left FEF 
activity and ↓ IPS and 
VMPFC activity; n.s. at 
T1 relative to CTRL 
Patients (T0 vs. T1); 
Patients (T1) vs. 
CTRL (T1)
Prosaccade vs. 
fixation
At T1 relative to CTRL, 
↓ supramarginal gyri*, 
insula*, DLPFC*, SEF† 
and ACC activity
Patients (T0 vs. T1); 
Patients (T1) vs. 
CTRL (T1)
Prosaccade vs. 
fixation
Ikuta et al. 
(74)
FEP 14 – 14; T0 
and T1
Randomized 
double-blind trial
Risperidone or 
aripiprazole (n 
not specified)
12 weeks Multi-source 
inference task
Over time, ↑ response 
accuracy; at T1 relative 
to CTRL, ↓ accuracy
Over time, ↓ SFG 
activity; ↑ left SFG and 
rostral PFC activity
Patients (T0 vs. T1) Interference vs. 
control
Keedy et al. 
(73)
FEP 14 – 12; T0 
and T1
Open-label trial Risperidone 
(n = 12), 
aripiprazole 
(n = 2)
4–6 weeks Visual attention 
task
No (between-
group) differences 
in prosaccade task 
performance (over time)
Over time, ↑ SEF, IPS 
and SPC activity; at T1 
relative to CTRL, n.s. 
group differences
Patients (T0 vs. T1); 
Patients (T1) vs. 
CTRL (T1)
Prosaccade vs. 
fixation
Over time, ↑ 
anticipatory saccades 
during predictive 
saccade task; at T1 
relative to CTRL, n.s. 
differences
Over time, ↑ left IPS 
activity and ↓ DLPFC 
activity; n.s. group 
differences
Patients (T0 vs. T1); 
Patients (T1) vs. 
CTRL (T1)
Predictive 
saccade vs. 
fixation
TABLe 1 | Continued
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Reference Diagnosis N 
(treated)
N 
(PLC 
arm)
N 
(CTRL 
arm)
Study design Treatment Duration Task Main behavioral 
results
Main fMRi results Timepoint 
and/or group 
comparisons
Task contrast
Benzodiazepines
Wilcox et al. 
(75)
Alcohol use 
disorder; 
comorbid 
anxiety
7 – 9; T0 Open-label trial Lorazepam plus 
disulfiram
5–7 days Multimodal 
stroop task
Overall relative to CTRL 
at T0, ↑ reaction times
Over time, ↓ right IPL 
and insula deactivity
Lorazepam + 
disulfiram (T0 vs. T1)
Incongruent vs. 
congruent (Scan 
1), incongruent 
+ congruent 
(Scan 2)
COMT inhibitors
Ashare et al. 
(76)
Smoking 
dependence 
(24-h abstinent)
20 – – Randomized 
double-blind 
PLC-controlled 
crossover design
Tolcapone 8 days n-back On tolcapone relative to 
PLC, ↑ accuracy
On tolcapone relative 
to PLC, ↑ VMPFC 
deactivity
Patients (tolcapone 
vs. PLC)
0 + 1 + 2 + 3 
back vs. baseline
On tolcapone relative to 
PLC, ↑ reaction times 
for Val/Val, ↓ reaction 
times for Val/Met
On tolcapone relative 
to PLC, ↓ MFG activity 
and ↑ VMPFC deactivity 
in Val/Val
Patients (tolcapone, 
PLC) for genotype 
(Val/Val, Val/Met)
0 + 1 + 2 + 3 
back vs. baseline
and ↑ MFG and right 
DLPFC activity in Val/
Met
Grant et al. 
(77)
Pathological 
gambling
12 – 12; T0 Open-label trial Tolcapone 8 weeks Tower of 
London task
No overall between-
group differences in 
task performance
Over time, ↑ fronto-
cingulo-parietalH activity; 
at T1, fronto-cingulo-
parietalH activity 
normalized to CTRL 
at T0
Tolcapone (T0 vs. 
T1); tolcapone (T1) 
vs. CTRL (T0)
Planning 
condition 
vs. counting 
condition
Nicotinic receptor agonists
Tregellas 
et al. (79)B
SCZ (non-
smoking; 
antipsychotics)
16 – – Randomized 
double-blind 
PLC-controlled 
crossover design
Varenicline 4 weeks Visual attention 
task
– – – –
Tregellas 
et al. (80)B
SCZ (non-
smoking; 
antipsychotics)
16 – – Randomized 
double-blind 
PLC-controlled 
crossover design
DMXB-A 4 weeks Visual attention 
task
– On DMXB-A 150 and 
75 mg relative to PLC, 
↓ IPL and MFG DMN 
activity and ↑ precuneus 
DMN activity
Patients (150 mg vs. 
PLC; 75 mg vs. PLC)
During 
prosaccade and 
rest
Loughead 
et al. (78)
Smoking 
dependence 
(72-h abstinent)
22 – – Randomized 
double-blind 
PLC-controlled 
crossover design
DMXB-A 13 days n-back On varenicline 
relative to PLC, ↓ 
reaction times in 
highly dependent 
smokers, but not lowly 
dependent smokers
On varenicline relative to 
PLC, ↑ ACC and DLPFC 
activity;↓ PFC activity 
(peak in right SFG and 
left IFG)
Patients (varencline 
vs. PLC)
3-back vs. 
0-back, 2-back 
vs. 0-back, 
1-back vs. 
0-back
TABLe 1 | Continued
(Continued)
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Reference Diagnosis N 
(treated)
N 
(PLC 
arm)
N 
(CTRL 
arm)
Study design Treatment Duration Task Main behavioral 
results
Main fMRi results Timepoint 
and/or group 
comparisons
Task contrast
Norepinephrine reuptake inhibitors
Schulz et al. 
(81)
ADHD (pediatric) 16 – – Randomized 
double-blind trial
Atomoxetine; 
MPH 
comparison 
(n = 18)
6–8 weeks Go/No Go Over time and similar 
to MPH, ↑ accuracy on 
No Go trials
Over time and similar to 
MPH, ↓ M1 activity
Atomoxetine (T0–T1) 
vs. methylphenidate 
(T0–T1)
Go vs. No Go
Over time and similar 
to MPH, ↓ reaction 
time and reaction time 
variability on Go trials
Over time and relative 
to MPH, ↑ right IFG, 
left ACC, left SMA, and 
PCG activity (MPH ↓ 
activity in these regions)
Atomoxetine (T0–T1) 
vs. methylphenidate 
(T0–T1)
Go vs. No Go
Bush et al. 
(82)
ADHD (adults) 11 10 – Randomized trial Atomoxetine; 
MPH 
comparison 
(n = 11)
6 weeks Multi-source 
interference 
task
No differences in task 
performance (over time)
Over time, ↑ right 
DLPFC, left IPL, left 
SMA, and left insula 
activity
Atomoxetine (T0 
vs. T1)
Interference vs. 
control
Chou et al. 
(83)
ADHD (pediatric) 22 – 20; T0 Randomized trial Atomoxetine; 
MPH 
comparison 
(n = 20)
12 weeks Stroop 
Counting Task
Over time and similar to 
MPH, ↓ reaction time 
during incongruent 
trials
Over time relative to 
MPH, greater ↑ in left 
dorsal ACC and DLPFC 
activity and smaller ↓ in 
left IFG activity
Atomoxetine (T0, T1) 
vs. methylphenidate 
(T0, T1)
Incongruent vs. 
congruent
Wagner 
et al. (66)D
Major 
depression
8 – 20; T0 Open-label trial Reboxetine 6 weeks Stroop color-
word task
Over time, larger ↑ 
in reaction time for 
incongruent trials, 
relative to congruent 
trialsF
– – –
Friedman 
et al. (84)
SCZ (atypical 
antipsychotics)
5 3 – Randomized 
double-blind PLC-
controlled design
Atomoxetine 
adjunctive 
treatment; PLC 
(n = 3)
8 weeks n-back – At T1 relative to PLC 
patients, ↑ left DLPFC 
activity
Atomoxetine (T1) vs. 
PLC (T1)
2-back + 3-back 
vs. 0-back
α2A adrenergic receptor agonists
Bedard et al. 
(85)
ADHD (pediatric) 12 13 – Randomized 
double-blind PLC-
controlled trial
Guanfacine 6–8 weeks Go/No Go No differences in task 
performance (over time)
Over time relative to 
PLC patients, n.s. 
differences
Guanfacine (T0, T1) 
vs. PLC (T0, T1)
Go vs. No Go
*Appeared; not present at T0, present at T1.
†Remained; present at T0 and T1.
↑, increased or higher; ↓, decreased or lower; T0, baseline; T1 and T2, follow-up; CTRL, healthy volunteers; PLC, placebo-treated; MPH, methylphenidate; FC, functional connectivity; DMN, default mode network. Psychiatric disorder: 
ADHD, attention-deficit/hyperactivity disorder; BD, bipolar disorder; OCD, obsessive–compulsive disorder; FEP, first-episode psychosis; SCZ, schizophrenia.
Brain regions: ACC, anterior cingulate cortex; DLPFC, dorsolateral prefrontal cortex; DMPFC, dorsomedial prefrontal cortex; FC, frontal cortex; IFG, inferior frontal gyrus; IPL, inferior parietal lobule; IPS, intraparietal sulcus; M1, primary 
motor area; MFC, medial frontal cortex; MFG, medial frontal gyrus; OFC, orbitofrontal cortex; PC, parietal cortex; PFC, prefrontal cortex; SEF, supplementary eye fields; SFG, superior frontal gyrus; SMA, supplementary motor area; 
SPL, superior parietal lobule; VLPFC, ventrolateral prefrontal cortex; VMPFC, ventromedial prefrontal cortex. 
A,BIdentical sample. C,DPart of same investigation. E,FSignificant effect/association in combined sample. GConsists of ACC, DLPFC, premotor cortex, and PC. HConsists of DLPFC, IPL, and frontopolar cortex.
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Anticonvulsants
We identified three manuscripts investigating the effect of 
anticonvulsants on the functional brain correlates of executive 
functions. All studies were conducted in pediatric bipolar 
disorder (age <18 years). A total of 34 pediatric patients were 
scanned before and after treatment. Thirteen patients were 
treated with lamotrigine, 11 with divalproex, and 10 with 
carbamazepine.
Bipolar Disorder
Pavuluri et al. (61) reported that, on a response inhibition task, 
pediatric bipolar patients displayed poorer overall (i.e., aver-
age of baseline and follow-up) accuracy on No-Go trials than 
healthy volunteers. However, similar to healthy volunteers, 
performance accuracy on Go trials increased from baseline to 
follow-up. From baseline to follow-up and compared to healthy 
volunteers, bipolar patients showed greater increases in left 
PFC and right medial frontal gyrus activity. At follow-up rela-
tive to healthy volunteers, increased left motor cortex activity 
appeared.
Another study by Pavuluri and colleagues (62) investigated the 
effect of divalproex on response inhibition and related functional 
connectivity. When divalproex-treated patients were combined 
with a parallel arm of risperidone-treated patients (see Atypical 
Antipsychotic treatment in Bipolar Disorder), discrimination 
sensitivity during a Go/No-Go task at baseline was poorer in 
patients than in healthy volunteers, but seemed to have normal-
ized at follow-up. From baseline to follow-up and compared 
to healthy volunteers, divalproex-treated patients showed a 
greater increase in left subgenual ACC and left insula functional 
connectivity in an affective network. Directly comparing the 
divalproex- and risperidone-treated patient group, the latter 
group showed a trend-significant greater increase in left insula 
functional connectivity in the affective network.
Finally, carbamazepine-treated patients displayed poorer 
accuracy on a sustained attention task at baseline and follow-up 
compared to healthy volunteers at baseline (63). An increase in 
sustained attention-related anterior PFC from baseline to follow-
up was observed. At follow-up, no significant differences were 
observed in anterior PFC activity compared to healthy volunteers 
at baseline.
Antidepressants: Selective Serotonin 
Reuptake inhibitors and Serotonin–
Noradrenaline Reuptake inhibitors
For treatment with selective serotonin reuptake inhibitors 
(SSRIs) and serotonin–noradrenaline reuptake inhibitors 
(SNRIs), six manuscripts were identified. Four studies were 
conducted in mood disorders, with a total of 124 patients 
scanned before and after treatment. Two studies were con-
ducted in OCD, with a total of 24 patients scanned before and 
after treatment. Medication type distribution was as follows: 
35 escitalopram (26 mood disorders), 31 venlafaxine (26 mood 
disorders), 27 sertraline (all mood disorders), 22 paroxetine (13 
mood disorders), 21 fluoxetine (20 mood disorders), and 12 
citalopram (all mood disorders).
Mood Disorders
On an n-back task, major depression patients compared to healthy 
volunteers had slower reaction times at baseline, which did not 
change after 2 and 8  weeks of SSRI treatment (64). However, 
compared to healthy volunteers, performance accuracy on the 
3-back condition increased over time. Compared to healthy 
volunteers and over time, no activity changes in the fronto-
cingulo-parietal cognitive control network were observed.
Aizenstein and colleagues (65) investigated the effect of 
SSRI treatment on task performance and brain activity during 
the preparing to overcome prepotency (spatial incompatibility) 
task, which assesses cognitive control. Compared to healthy 
volunteers at baseline, poorer performance accuracy at follow-up 
was observed in the sample of late-life depression patients treated 
with paroxetine. From baseline to follow-up, rule applying-
related DLPFC, but not response overriding-related ACC, activ-
ity increased in patients. At follow-up, DLPFC activity was still 
lower than healthy volunteers at baseline.
Wagner et al. (66) investigated the effects of SSRI treatment 
on Stroop task performance and attention and interference-
related brain activity. The decrease in response time between 
baseline and follow-up was greater for incongruent trials than 
for congruent trials when the SSRI-treated sample was combined 
with a sample receiving noradrenaline reuptake inhibitors (NRIs; 
see Noradrenaline Reuptake Inhibitors treatment in Major 
Depression). From baseline to follow-up, SSRI treatment was 
associated with widespread decreases in the fronto-cingulo-pari-
etal network during the incongruent condition of the Stroop task 
(Table 1). When SSRI- and NRI-treated patients were combined, 
no differences in brain activity during the incongruent condition 
were observed at follow-up, relative to healthy volunteers.
In a large multicenter endeavor, healthy volunteers and 
remitted depression patients (treated with SSRIs or SNRIs) 
showed a decrease in response inhibition-related DLPFC activity 
from baseline to follow-up (67). Relative to healthy volunteers 
and remitters, non-remitters displayed DLPFC hypoactivity at 
baseline, which did not increase at follow-up. SSRI remitters and 
healthy volunteers showed a similar decrease in IPL activity from 
baseline to follow-up. At baseline, SNRI remitters compared to 
SSRI remitters and healthy volunteers displayed IPL hypoactiv-
ity, which did not increase to the level of healthy volunteers at 
follow-up.
Obsessive–Compulsive Disorder
Relative to non-responders, SSRI or SNRI treatment responders 
displayed increased performance accuracy on the n-back over 
time (68). From baseline to follow-up, responders relative to non-
responders correspondingly displayed decreased activity in the 
fronto-cingulo-parietal network during the 1-back and 2-back 
condition.
Using a task-switching paradigm, Han et al. (69) showed that 
task-switching costs (task-switching reaction time −  task-repeat 
reaction time) decreased in SSRI-treated patients from baseline 
to follow-up. However, patients displayed poorer accuracy at 
baseline and follow-up than healthy volunteers at baseline. From 
baseline to follow-up, task-switching activity increased in the 
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fronto-cingulo-parietal network (Table 1). Compared to healthy 
volunteers at baseline, decreased frontal and parietal activity 
remained and increased insular activity appeared at follow-up 
(Table 1).
Atypical Antipsychotics
For treatment with typical and atypical antipsychotics, seven 
manuscripts were identified. Two studies were conducted in 
bipolar disorder, with a total of 21 patients scanned before and 
after treatment. The remaining five studies were conducted in 
psychotic disorders, with a total of 60 patients scanned before and 
after treatment. The 36 patients received risperidone (11 bipolar), 
11 ziprasidone (10 bipolar), 13 quetiapine, 3 olanzapine, 2 halo-
peridol, and 2 aripiprazole. Another 14 patients with psychotic 
disorder received either risperidone or aripiprazole, but numbers 
for each treatment were not reported.
Bipolar Disorder
In addition to divalproex (see Anticonvulsant treatment in 
Bipolar Disorder), Pavuluri and colleagues (62) also investigated 
the effect of risperidone on response inhibition-related functional 
connectivity in pediatric mania. From baseline to follow-up and 
compared to healthy volunteers, a greater increase in insular 
functional connectivity during response inhibition was observed 
in an affective functional connectivity network.
Schneider et  al. (63) investigated the effect of ziprasidone 
on sustained attention in pediatric mixed/mania patients. 
Performance parameters on the continuous performance task 
(identical pairs version, similar to 1-back task) did not differ 
among treatment and control groups (over time). From baseline 
to follow-up and compared to a placebo-treated patient group, 
the zipradisone-treated group showed a larger increase in right 
sustained attention-related VLPFC and OFC activity. At days 7 
and 28, no significant differences in sustained attention-related 
brain activity were observed between the entire patient sample 
(ziprasidone plus placebo) and healthy volunteers at baseline.
Psychotic Disorders
In another study using the preparing to overcome prepotency task, 
SCZ patients compared to healthy volunteers displayed increased 
reaction times at baseline and follow-up (70). From baseline to 
follow-up, response overriding-related ACC activity increased in 
SCZ patients, whereas rule applying-related DLPFC activity did 
not. At follow-up, task-induced ACC and DLPFC activity was 
comparable between SCZ patients and healthy volunteers.
In an open-label quetiapine trial, performance on the n-back 
task did not improve over time (71). However, task-induced left 
VLPFC and right precuneus activity increased in SCZ patients 
from baseline to follow-up.
Following treatment with atypical antipsychotics, Keedy et al. 
(72) reported activity normalization in anterior frontal and pari-
etal areas during a visual attention task (Table 1). At follow-up, 
not all activity had normalized: compared to healthy volunteers, 
widespread reductions in fronto-cingulo-parietal activity had 
appeared or remained in SCZ patients (Table 1).
In a second study by Keedy et al. (73), patients and healthy 
volunteers did not differ in performance on the same visual 
attention task at baseline or follow-up. Activity in supplemen-
tary eye fields and parietal cortex normalized from baseline to 
follow-up (Table  1). During a presaccadic task, which probes 
frontostriatal motor and attention functions, increased left pari-
etal and decreased DLPFC activity was observed from baseline 
to follow-up.
A final study using atypical antipsychotics in first-episode 
psychosis reported increased accuracy over time on an atten-
tion control task, which was still poorer than healthy volunteers 
at follow-up (74). In PFC, left SFG and anterior PFC activity 
increased from baseline to follow-up, although decreases in SFG 
activity were also reported.
Benzodiazepines
We identified one manuscript using lorazepam plus disulfiram in 
substance dependence with comorbid anxiety disorder. A total of 
seven patients were scanned before and after treatment.
Alcohol Use Disorder
On a multisensory Stroop task, alcohol use disorder patients 
displayed overall slower reaction times than healthy volunteers 
at baseline (75). While at baseline, alcohol use disorder patients 
displayed attention and interference-related deactivity in parietal 
areas, there was slight activity at follow-up (i.e., decreased deac-
tivity) (Table 1).
Catechol-O-Methyl Transferase inhibitors
For treatment with catechol-O-methyl transferase (COMT) 
inhibitors, two studies were identified. One study was carried 
out in smoking dependence; the other was carried out in patho-
logical gambling. The 32 patients were scanned before and after 
tolcapone treatment.
Smoking Dependence
In a randomized double-blind placebo-controlled crossover 
design, Ashare et  al. (76) observed that performance accuracy 
on the n-back task, relative to placebo, increased after 8 days of 
treatment with tolcapone. Relative to placebo, patients displayed 
increased ventromedial PFC (VMPFC) deactivity. On tolcapone 
relative to placebo, Val/Val carriers of the COMT gene displayed 
decreased medial PFC (MPFC) activity and increased (i.e., more) 
VMPFC deactivity during the task, while Val/Met carriers dis-
played increased VMPFC and right DLPFC activity.
Pathological Gambling
Pathological gambling patients and healthy volunteers showed 
similar overall accuracy on a Tower of London planning task (77). 
From baseline to follow-up, planning-related fronto-cingulo-
parietal activity increased and seemingly normalized to that of 
healthy volunteers at baseline (Table 1).
Nicotinic Receptor Agonists
We identified three papers (two unique samples) using nicotinic 
receptor agonists, with a total of 38 patients scanned before and 
after treatment. One study used α4β2 nicotinic receptor agonist 
varenicline in 22 smoking-dependent individuals. Another study 
used 3-(2,4-dimethoxybenzylidene)-anabaseine (DMXB-A), 
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a partial α7 nicotinic agonist, as an adjunctive treatment in 16 
non-smoking SCZ patients on stable antipsychotic treatment.
Smoking Dependence
Response times for correct trials on the n-back decreased on 
varenicline relative to placebo in highly dependent abstinent 
smokers, but not in their lowly dependent counterparts (78). 
Moreover, on varenicline relative to placebo, MPFC and DLPFC 
activity increased, specifically on the 2-back and 3-back level. In 
addition, whole brain analyses revealed frontal cortex activity 
decreases on varenicline relative to placebo, with peak deactiva-
tions detected in the right SFG and left IFG.
Psychotic Disorders
Relative to placebo, no changes in the fronto-cingulo-parietal 
network were observed during a visual attention task after 
a 1-month treatment with 75 and 150  mg of DMXB-A (79). 
However, differences in frontal and parietal default mode net-
work activity were observed between the placebo and DMXB-A 
session (Table 1) (80).
Noradrenaline Reuptake inhibitors
For treatment with NRIs, five studies were identified. Three studies 
were conducted in ADHD (two pediatric and one adult sample), 
one in major depression, and one in SCZ (adjunctive treatment). 
A total of 64 patients were scanned before and after treatment, 
of which 56 received atomoxetine and 8 received reboxetine (all 
major depression).
Attention-Deficit/Hyperactivity Disorder
Similar to MPH-treated patients, accuracy increased on No-Go 
trials from baseline to follow-up in those receiving atomoxetine 
(81). Moreover, reaction times and reaction time variability 
decreased. From baseline to follow-up and similar to the MPH-
treated group, primary motor cortex activity decreased during 
the response inhibition task. MPH and atomoxetine seemed to 
produce differential effects on the fronto-cingulo-parietal cogni-
tive control network (Table 1): atomoxetine increased and MPH 
decreased activity from baseline to follow-up.
Bush et  al. (82) reported that performance on an attention 
control task did not change over time or relative to placebo-
treated patients. From baseline to follow-up, frontal cortical and 
parietal activity (Table 1) during an interference task increased 
in an atomoxetine-treated cohort of patients.
Similar to MPH-treated patients, reaction times on a Stroop 
task decreased over time in atomoxetine-reated patients (83). 
At brain level, differential effects of MPH and atomoxetine were 
observed. From baseline to follow-up and relative to MPH, 
greater increases in left DLPFC and ACC activity and a smaller 
increase in left IFG activity were reported.
Major Depression
In addition to SSRIs (see Antidepressant treatment in Mood 
Disorders), Wagner et al. (66) also investigated the effects of NRIs 
on response interference-related brain activity. Whereas SSRIs 
decreased fronto-cingulo-parietal network activity (Table  1), 
reboxetine did not.
Psychotic Disorders
Friedman et al. (84) investigated the effect of adjunctive atom-
oxetine pharmacotherapy on n-back-related brain activity in 
SCZ patients on stable treatment with atypical antipsychotics. 
Performance parameter changes were not observed among 
groups or over time. At follow-up relative to placebo-treated 
patients, increases in left DLPFC activity were observed.
Noradrenergic Receptor Agonists
We identified one paper using α2A noradrenergic receptor agonist 
guanfacine, investigating 12 pediatric ADHD patients before and 
after treatment.
Attention-Deficit/Hyperactivity Disorder
From baseline to follow-up and compared to placebo-treated 
patients, 6- to 8-week treatment with guanfacine was not 
associated with improved accuracy, reaction times, or response 
inhibition-related brain activity in the fronto-cingulo-parietal 
network (85).
DiSCUSSiON
The aim of this systematic review was to summarize the impact 
of pharmacological interventions for psychiatric disorders on the 
fronto-cingulo-parietal cognitive control network and to relate 
this to plausible neurochemical mechanisms of action. Here, we 
will first discuss the evidence per treatment class, followed by a 
review of transdiagnostic commonalities as potential markers for 
future procognitive treatments.
Pharmacological interventions, Their 
effects on Functional Brain Correlates of 
executive Functions and 
Neuropharmacological Mechanism
Cholinergic Targets
Despite the pivotal role of acetylcholine in executive functions 
(86, 87), few potentially procognitive cholinergic agents are cur-
rently available, with actylcholinesterase inhibitors and nicotinic 
receptor agonists used most frequently.
Acetylcholinesterase Inhibitors
With a placebo-controlled and placebo-controlled crossover 
design, the available preliminary evidence for adjunctive ace-
tylcholinesterase inhibitors in SCZ was of good quality. In line 
with a large number of placebo-controlled clinical trials (88–92), 
adjunctive rivastigmine or donepezil treatment did not improve 
performance on attention and working memory tasks in SCZ. 
Moreover, in contrast to studies in Alzheimer’s disease (93, 94), 
two out of three manuscripts did not report task-related increases 
in fronto-cingulo-parietal activity (59, 60). Only Nahas et al. (58) 
observed increased IFG activity during a verbal fluency task after 
12 weeks of treatment, a region also previously associated with 
verbal fluency (95) and likely associated with the Go/No-Go 
behavior required for this task. Kumari et  al. (60) observed 
increased left SFG activity in placebo-treated patients over 
time, but not in the rivastigmine-treated patient group. These 
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between-study differences may be explained by sample size (6 vs. 
11 participants) or task demands, with verbal fluency tasks being 
dependent on lexical access speed and vocabulary size (96), in 
addition to attention and working memory.
There was, however, evidence for increases in occipital cortex 
and cerebellum activity (58, 59), previously reported to be related 
to visual attention, stimulus encoding, or motor speed (97, 98). 
Indeed, meta-analytic evidence suggests that acetylcholinester-
ase inhibitors may increase motor speed in SCZ (99), possibly 
explaining increased cerebellar activity.
The absence of any marked and consistent effects of acetyl-
cholinesterase inhibitors on the fronto-cingulo-parietal cognitive 
control network in SCZ may be related to the suspected abnor-
malities in the cholinergic system. In SCZ, abnormalities have 
been observed at the receptor level, with evidence for a decrease 
in α7 nicotonic (100), β2 (101), and muscarinic receptors (102). 
Acetylcholinesterase inhibition, compared to direct targeting of 
receptors, may therefore not be the most efficient way to improve 
executive functions in SCZ. Second, tobacco desensitizes α7 and 
α4β2 nicotonic receptors (103, 104) and many participants in the 
available studies smoked tobacco. This could further decrease the 
procognitive potential of acetylcholinesterase inhibitors, although 
upregulated β2 receptors in smoking SCZ have also been associ-
ated with improved executive functions (105), requiring further 
investigation. Finally, all participants were already on atypical 
antipsychotics, which have been shown to increase frontal cortex 
acetylcholine release (106), fronto-cingulo-parietal activity (107, 
108), and modestly improve performance on neuropsychological 
tests (36) (also see Atypical Antipsychotics), perhaps indicating 
a ceiling effect.
Thus, the current preliminary evidence suggests that adjunc-
tive acetylcholinesterase inhibitors in SCZ do not markedly 
impact the fronto-cingulo-parietal cognitive control network, 
but may increase occipital cortex and cerebellum activity. Given 
the quality of the available evidence, these results likely reflect 
treatment effects, rather than practice or iatrogenic effects. In 
order to determine if the cholinergic system can be targeted to 
increase executive functions in SCZ, selective and direct target-
ing of nicotinic and muscarinic receptors may be a more fruitful 
strategy, although lack of specificity for the receptor subtypes has 
hampered the development of suitable drugs.
Nicotinic Receptor Agonists
The only available study for acetylcholine nicotinic receptor ago-
nists in smoking dependence was a placebo-controlled crossover 
design, which reported decreased n-back reaction times in highly 
dependent smokers while on varenicline. Moreover, on vareni-
cline relative to placebo, DLPFC and ACC activity increased 
in the entire sample of smoking-dependent individuals, while 
activity in other frontal cortical areas decreased. Modulation of 
these areas is in line with recent meta-analytic evidence and likely 
reflects varenicline’s ability to optimize activity of the cognitive 
control network while suppressing task-irrelevant activity of the 
default mode network (109). Behaviorally, these observations 
are in agreement with repeated dosing evidence showing that 
varenicline improves several aspects of executive functions in 
smokers (110–112) and non-smokers (113). Varencline’s ability 
to modulate fronto-cingulo-parietal activity is promising and 
eagerly awaits replication in other psychiatric disorders.
In non-smoking SCZ patients, partial α7 agonist DMXB-A 
was not associated with activity changes in the fronto-cingulo-
parietal network during a visual attention task. However, task-
related changes in hippocampal activity (79) and suppression 
of default mode network activity in frontal cortical and parietal 
areas (80) were observed. While no other data for SCZ were avail-
able, the trial evidence for DMXB-A (114, 115) and varenicline 
(116–120) in psychotic disorders has been mixed, perhaps related 
to underlying cholinergic abnormalities or smoking status. Here, 
the use of fMRI and neuropsychological tasks that emphasize 
working memory, response inhibition, and action selection abili-
ties could be useful in assessing DMXB-A’s potential procognitive 
abilities in SCZ.
Varenicline is a nicotinic receptor partial agonist at α4β2 recep-
tors and full agonist at α7 receptors, and DMXB-A is a partial ago-
nist at α7 receptors. Both β2- and α7-selective compounds increase 
frontal cortex dopamine release in the rat (121), offering an expla-
nation for varenicline and DMXB-A’s putative activity- modulating 
abilities in frontal cortical areas. Neuropharmacologically, α7 and 
α4β2 in frontal cortex (121), α4β2 receptors expressed on ventral 
tegmental area neurons (122) and α7 receptors expressed on glu-
tamatergic projections to the ventral tegmental area (123) seem to 
underlie the increase in dopamine release.
Anticonvulsants
While anticonvulsants were originally developed to treat epileptic 
seizures, the majority of them have been shown to exert mood-
stabilizing effects in bipolar (124, 125). Given that modulation 
of glutamatergic and γ-aminobutyric acid (GABA) activity is 
a common mechanism of these agents, and that excessive PFC 
glutamatergic signaling may contribute to cognitive impairments 
(126), it seems plausible to suggest that they could modulate 
executive functions.
With two open-label trials and one placebo-controlled study, 
the evidence for anticonvulsants in bipolar disorder was of mod-
erate quality. In the open-label trials, there was no evidence for 
improvements in task performance (61, 63). This is in contrast 
to the only available placebo-controlled study, where divalproex 
treatment seemingly normalized response inhibition, but only 
when combined with a parallel group of risperidone-treated 
bipolar patients (62).
In the open-label trials, widespread normalization (increases) 
of anterior PFC and MPFC hypoactivity was observed after 
anticonvulsant treatment (61, 63). However, practice and placebo 
effects could not be excluded because of the lack of a placebo-
controlled group and absence of prospective data for healthy 
volunteers (Table 1). In line with the findings of increased PFC 
activity in the open-label studies, subgenual ACC and insular 
functional connectivity increased during a Go/No-Go task in the 
placebo-controlled study (62). The regional specificity of these 
findings is noteworthy, given the consistent involvement of the 
ACC and insula in conflict monitoring and response inhibition 
(30). This may point toward treatment effects, but it is important 
that the findings for carbamazepine and lamotrigine are now 
replicated in placebo-controlled studies.
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The inhibitory actions of lamotrigine, carbamazepine, and 
sodium valproate (127–130) at ion channels and N-methyl-d-
aspartate (NMDA) receptors (131) are essential in modulating 
extracellular glutamate and GABA concentrations. Magnetic 
resonance spectroscopy studies in bipolar disorder have revealed 
alterations in frontal cortex, particularly ACC, glutamate, and 
glutamine concentrations (132, 133). Moreover, treatment with 
anticonvulsants (132), notably divalproex (134), alters VLPFC 
and ACC glutamate and glutamine levels, reflecting changes in 
glutamate concentrations, GABA concentrations, or both.
Summarizing, there is preliminary evidence that anticon-
vulsants impact, specifically increase, fronto-cingulo-parietal, 
especially ACC, activity in bipolar disorder, possibly reflecting 
changes in glutamate and/or GABA release at the neuronal level, 
and increased response inhibition at the behavioral level.
Antidepressants
Although impressive in total sample size, the quality of evidence 
for antidepressants in depression and OCD was suboptimal, with 
five out of six studies employing an open-label design. Moreover, 
four out of six studies only had access to healthy control data at 
baseline or did not utilize a control group (Table 1). This compli-
cates interpretation of the findings and increases susceptibility to 
practice, placebo and, more generally, iatrogenic effects.
With the exception of one study reporting a greater increase in 
3-back performance over time in patients vs. healthy volunteers 
(64), there was no evidence for improved task performance fol-
lowing antidepressant treatment in depression. These results are 
generally in line with clinical trials showing no marked effects of 
antidepressants on cognitive control in depression (135), a domain 
that all available studies in depression assessed. Nonetheless, they 
are puzzling, given the presence of response inhibition deficits 
in depression (136), the proposed role of serotonin in inhibitory 
control (40), and the observation that serotonergic manipulations 
modulate the cognitive control network in healthy volunteers 
(137–139).
Two studies in depression reported activity decreases over 
time, observing normalized DLPFC activity during a response 
inhibition task (67) and normalized frontal cortical and parietal 
activity during an interference/conflict resolution task (66) fol-
lowing antidepressant treatment. Moreover, there was an overall 
greater engagement of frontoparietal regions with increasing 
n-back difficulty in patients vs. healthy volunteers (64), consist-
ent with the observation of DLPFC hyperactivity during the 
n-back task in untreated depression (140). Taken together, these 
data suggest that SSRIs decrease frontal cortical and parietal 
hyperactivity in treatment responders, in spite of any marked 
performance changes.
A modest increase in DLPFC activity was observed during a 
cognitive control task, which at follow-up was still lower than 
healthy volunteers at baseline (65). The reported increase in 
DLPFC activity could have been attenuated by practice effects, 
given that steady declines in task-related activity have been 
reported over time in healthy volunteers (64, 67) and the fact that 
this study only had access to healthy volunteer data at baseline. 
Moreover, the seemingly contrasting observations of increased 
and decreased PFC activity may also be related to diagnosis: 
DLPFC activity increases were observed in late-life depression, 
while studies reporting anterior PFC decreases were conducted 
in major depression (Table 1). A final explanation could be the 
significant variation in treatment duration, ranging from 6 to 
12 weeks, which is especially noteworthy in light of the delayed 
actions of SSRIs (141, 142).
Serotonin–noradrenaline reuptake inhibitor treatment in 
depression did not seem to impact fronto-cingulo-parietal activ-
ity (67). This is in line with the only available study in depression 
directly comparing serotonergic and noradrenergic agents (66), 
where SSRIs were associated with decreased parahippocampal 
and amygdalar activity, and reboxetine with slightly increased 
activity in these regions (NRIs in other disorders discussed in 
Section “Noradrenaline Reuptake Inhibitors”). The differential 
effect of SSRIs, SNRIs, and NRIs on attention and cognition-
related brain function may be related to regional variation in 
serotonin transporter (143), noradrenaline transporter (144), 
and serotonin receptor subtype 1A (5HT1A) (145) expression. 
Still, they are surprising in light of the well-established modulat-
ing effects of NRIs on fronto-cingulo-parietal, specifically IFG, 
activity in ADHD (81, 83), and healthy volunteers (146).
All in all, the available results in depression suggest an effect of 
serotonergic treatment on the fronto-cingulo-parietal cognitive 
control network, but interpretation is severely hampered by a lack 
of randomized double-blind trials. In the absence of clear perfor-
mance changes, we speculate that these activity changes could 
reflect improvement in the affective domain. Indeed, fronto-
cingulo-parietal activity (changes) correlated with Hamilton 
Rating Scale for Depression scores (64, 66), and ACC metabolism 
predicts treatment response in depression (147).
The preliminary results in OCD were mixed on the level of 
performance and activity (changes), which could be related to 
study design (open label vs. double blind) or reference group 
(treatment responder vs. healthy volunteers at baseline) (68, 69). 
There were some indications of performance improvements, such 
as increased accuracy, in SSRI/SNRI treatment responders (68) 
and decreased reaction times from baseline to follow-up (69). 
However, comparison with a control group over multiple time 
points is essential to disentangle practice effects from treatment 
effects.
Atypical Antipsychotics
The quality of the evidence for atypical antipsychotics was 
moderate: three out of seven studies employed a randomized 
double-blind design, and six out of seven studies had baseline 
and follow-up data of a control group (Table 1).
Especially in psychotic disorders, atypical antipsychotics have 
been associated with modest improvements in executive function 
domains such as response inhibition, planning, and immediate 
recall (36, 148, 149). One out of two included studies in bipolar 
disorder reported increased task performance, with risperidone-
treated patients showing comparable response inhibition to 
healthy volunteers but only when combined with a divalproex-
treated group (also see Anticonvulsants) (62). In psychotic disor-
der, only performance on a visual attention task normalised (73) 
and two studies reported no performance differences at baseline 
and follow-up, relative to healthy volunteers (71, 72). Thus, there 
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seems to be some overlap with clinical trials in terms of modestly 
improved executive functions on atypical antipsychotics.
Regardless of psychiatric disorder, the most consistent obser-
vation was increased, often normalized, anterior PFC (63, 70, 71) 
ACC (70), and parietal (73) activity following atypical antipsy-
chotics treatment, the great majority being risperidone. Increased 
fronto-cingulo-parietal activity has also been observed when 
SCZ patients were switched from typical to atypical antipsychot-
ics (107, 108) and from 4 to 8 weeks of treatment with olanzapine 
(150), all in all showing a consistent picture of increased fronto-
cingulo-parietal activity on atypical antipsychotics. Outside of 
the fronto-cingulo-parietal network, decreases in ventral (74) and 
dorsal (72) striatal activity were observed in psychotic disorder. 
A correlation between caudate activity and risperidone dose (73) 
was also reported, consistent with the notion that antipsychotics 
decrease striatal dopaminergic hyperactivity.
Atypical antipsychotics are thought to increase frontal cortex 
DA release via 5HT1A agonism (106, 151–153) and 5HT2A 
antagonism (154, 155). In addition, increased frontal cortex ace-
tylcholine and serotonin release has also been observed following 
administration of atypical antipsychotics (106, 151, 154). The 
observed increases in fronto-cingulo-parietal activity following 
atypical antipsychotics treatment may therefore be underlain by 
increased dopaminergic, serotonergic, and/or cholinergic activity 
in frontal cortex and their downstream effects. While the behavio-
ral, neuroimaging, and neuropharmacological evidence seems to 
point toward modest procognitive effects of atypical antipsychot-
ics, especially psychotic disorders are in need of replication with 
double-blind randomized designs to understand the exact extent 
of normalization within the fronto-cingulo-parietal network.
Benzodiazepines
With only one open-label study identified, the results for benzo-
diazepines were preliminary. There was no evidence for improved 
performance, and some hints at decreased parietal hyperactivity 
and decreased temporal hypoactivity at follow-up, although these 
activity changes might partly reflect practice effects.
Catechol-O-Methyl Transferase Inhibitors
A placebo-controlled crossover and open-label study were iden-
tified for COMT inhibitors, suggesting moderate quality of the 
available preliminary evidence.
One out of two studies reported performance changes; in 
smoking dependence, n-back performance accuracy increased 
on tolcapone, and there was an effect of COMT genotype on 
reaction times (76) (Table 1). Task-related activity changes were 
observed in both smoking dependence and pathological gam-
bling, with the former showing increased VMPFC deactivity on 
tolcapone (76) and the latter normalized fronto-cingulo-parietal 
hypoactivity, albeit to activity of healthy volunteers at baseline 
and in the absence of a placebo-controlled group (77). These 
results are in line with tolcapone’s effect in healthy volunteers, 
where it has been reported to increase n-back performance (156) 
and optimize task-related brain activity (156, 157).
Although preliminary and modest in nature, the results for 
COMT are favorable and could suggest potential procognitive 
effects that remain to be replicated in large placebo-controlled 
clinical trials. Interestingly, tolcapone does not affect extracel-
lular catecholamine concentrations when administered alone, 
but increases striatal and frontal cortex dopamine release after 
l-DOPA (158, 159) and clozapine (160) administration. This may 
suggest that the catecholamine-increasing effect of tolcapone 
on the fronto-cingulo-parietal network could be even greater 
in medicated individuals with Parkinson’s disease or psychotic 
disorder, opening up new avenues for adjunctive treatment.
Noradrenaline Reuptake Inhibitors
With three randomized studies (one reported to be double-
blind), all having included a MPH-treated patient group and one 
additional placebo-treated patient group (Table 1), the evidence 
for atomoxetine in ADHD was of moderate to good quality. In 
line with clinical trial evidence (35), increased performance on 
response inhibition tasks was observed following atomoxetine 
treatment (81, 83).
Meta-analytical evidence in ADHD suggests that MPH among 
others consistently impacts IFG, dorsal ACC, and SMA activity 
(30), which were all areas consistently modulated by atomoxetine 
treatment (Table 1) and involved in conflict monitoring, response 
inhibition, and action selection (40). There were, however, differ-
ences between the two agents, such that atomoxetine and MPH 
exerted opposing effects on the same regions (81, 82) or that 
atomoxetine modulated task-relevant activity in one part of the 
fronto-cingulo-parietal network (e.g., ACC and DLPFC activity), 
while MPHs actions affected another part of the network (e.g., 
IFG) (83).
These results suggest that atomoxetine and MPH impact com-
mon substrates of the fronto-cingulo-parietal network, but also 
have a certain local and global task-dependent uniqueness. One 
tentative explanation could be that atomoxetine and MPH have 
almost comparable procognitive effects via differing underlying 
neurochemical mechanisms. MPH and atomoxetine’s dopamine- 
and noradrenaline-increasing properties (161) are for a major part 
directed to D1 and α2A adrenergic receptors, the former involved 
in suppressing noise (162) and the latter in enhancing signal 
(163) of neuronal networks. Moreover, the atomoxetine-induced 
increase in noradrenaline levels in frontal cortex decreases after 
prolonged exposure, while this is not the case for MPH (164). 
The neuropharmacological properties of MPH and atomoxetine 
may differentially affect the reorganization of functional brain 
networks.
In contrast to amphetamine (165) and in line with previous 
work (166), adjunctive atomoxetine treatment in antipsychotics-
treated SCZ patients did not improve task performance. Despite 
any performance changes, task-related activity increases in 
DLPFC were observed, as well as an increase in posterior cin-
gulate gyrus activity. These are regions typically modulated by 
atomoxetine in ADHD (81). While preliminary, the combination 
of atypical antipsychotics and atomoxetine may have led to 
overstimulation of frontal cortex dopamine and noradrenaline 
release, thereby missing the narrow window in which frontal 
cortex dopamine and noradrenaline levels optimally mediate 
cognitive performance (163, 167). Replication with SCZ patients 
on typical antipsychotics or MPH as an adjunctive treatment may 
shed further light on these findings.
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Noradrenergic Receptor Agonists
While there were no main effects of α2A noradrenergic agonist 
guanfacine on response inhibition or associated brain function, 
this agent is clinically efficacious in treating symptoms of ADHD 
(168). Moreover, in smoking dependence, guanfacine modulates 
response inhibition and conflict resolution-related activity in 
among others SMA, DLPFC, VMPFC, and insula (169). In 
comparison to MPH and atomoxetine, guanfacine’s actions are 
confined to α2A noradrenergic receptors, thereby specifically 
enhancing signal in working memory networks (163). Direct 
comparison of guanfacine with atomoxetine and MPH could 
be valuable in elucidating the degree to which the latter two 
compounds modulate fronto-cingulo-parietal activity via a 
signal-increasing mechanism.
Common Transdiagnostic Changes in the 
Fronto-Cingulo-Parietal Network as 
indicators of Successful Treatment
While executive function deficits are a universal symptom of 
psychiatric disorders, the underlying causes are not known. What 
is clear is that executive functions are underlain by an intricate 
and widely distributed network of brain regions. Theoretically, 
alterations in any of these regions can negatively affect network 
integrity, thereby giving rise to executive function deficits. As a 
result, pharmacological treatment of executive function deficits 
remains complex, reflected in the unsatisfactory treatment across 
psychiatric disorders. We identified common transdiagnostic 
changes in fronto-cingulo-parietal activity, which could serve as 
treatment markers.
Despite differences in experimental designs, treatment dura-
tion, and dosage, there were notable transdiagnostic effects of 
pharmacological agents on the fronto-cingulo-parietal network. 
In studies that also showed beneficial behavioral effects, or for 
which clinical trial data suggested beneficial effects, common 
activity changes in the fronto-cingulo-parietal network were (I) 
enhancement of activity in task-relevant areas and (II) suppres-
sion of activity in task-irrelevant areas.
In smoking dependence, tolcapone further suppressed activ-
ity in task-irrelevant areas such as the VMPFC (76), while in 
pathological gambling, it increased task-relevant fronto-cingulo-
parietal activity (77). In line with the agent’s neuropharmacologi-
cal action, the exact nature of activity changes was dependent on 
COMT genotype (Table 1). Similarly, nicotinic receptor agonist 
varenicline increased DLPFC and ACC activity in smoking 
dependence (78) and suppressed parietal and frontal cortical 
default mode network activity in SCZ (80). Atomoxetine, in most 
cases, increased task-relevant activity in DLPFC, ACC, IFG, and 
IPL in ADHD (81–83). Lastly, atypical antipsychotics increased 
DLPFC, ACC, and parietal cortex activity (70, 73), and decreased 
VMPFC activity (72). Overall, these results suggest positive 
predictive value of increased task-related fronto-cingulo-parietal 
activity as a marker of successful pharmacological treatment.
These were also transdiagnostic commonalities that dis-
played a degree of negative predictive value. Notably, increased 
task-relevant DLPFC activity was observed after adjunctive 
atomoxetine treatment in SCZ, together with increased 
task-irrelevant posterior cingulate activity, a region thought to 
be associated with the default mode network (80). Moreover, 
in depression, non-remitters showed task-relevant DLPFC 
hypoactivity (67). Finally, acetylcholinesterase inhibitors in SCZ 
did not consistently modulate fronto-cingulo-parietal network 
activity (58–60).
A final common observation was that the effects of pharmaco-
logical agents on the fronto-cingulo-parietal network were often 
lateralized. Unilateral effects could be related to lateralization of 
frontoparietal networks at rest (170). Indeed, changes in unilateral 
frontoparietal networks have also been observed following dopa-
minergic challenges (171). Lateralized functional networks could 
be the result of lateralized projections at the cellular level, which 
has been shown for among others dopamine (172), serotonin 
(173), and glutamate (174). Assessing laterality of the observed 
activity changes could be helpful in determining the specificity 
of treatment effects.
Conclusion and Future Directions
The available evidence suggests that dopamine, noradrenaline, 
and acetylcholine agonists are most consistently associated 
with activity changes in the fronto-cingulo-parietal network, as 
measured with fMRI. Across disorders, increased activity in task-
relevant areas or decreased activity in task-irrelevant areas were 
the most consistent findings, demonstrated by good positive and 
moderate negative predictive value. However, in order to fully 
assess the potential of these markers, more randomized double-
blind studies are necessary.
The current review highlights the potential of a dimensional, trans-
diagnostic approach in future (pharmacological) neuroimaging stud-
ies, thereby paralleling a shift that is currently taking place in the field 
of clinical diagnostics and management. The search for procognitive 
agents has thus far been carried out within the context of categorical 
classifications, which has not lead to any major breakthroughs in the 
development of treatments.
A surprising observation was the lack of selective cholinergic, 
especially muscarinic, and glutamatergic, notably NMDA recep-
tor, agents. Preclinical and proof-of-concept trial evidence have 
demonstrated promising procognitive potential for M1 allosteric 
modulators (86, 175) and selective NMDA antagonists (176). 
The lack of clinical trial and neuroimaging evidence may reflect 
unavailability of such compounds or potential safety issues of the 
available compounds (177). A recent initiative that may facilitate 
testing of novel compounds is the Medicine Chest initiative by 
the ECNP (www.ecnp.eu), which could aid clinical researchers in 
gaining access to new pharmacological tools.
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